HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yusuke Tada Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Katoh, J. Articles by Tada, Y. Search for Related Content PubMed PubMed Citation Articles by Katoh, J. Articles by Tada, Y.

J Thorac Cardiovasc Surg 1998;116:312-316
© 1998 Mosby, Inc.

Cardiopulmonary Support and Physiology

Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass

From the Second Department of Surgery, Yamanashi Medical University,^a and the Department of Cardiovascular Surgery,^b Yamanashi Central Hospital, Yamanashi, Japan.

Received for publication June 3, 1997. Revisions requested Sept. 15, 1997; revisions received Feb. 25, 1998. Accepted for publication March 5, 1998. Address for reprints: Junya Katoh, MD, Second Department of Surgery, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakakoma-gun, Yamanashi, 409-3821 Japan.

Objective: Depressive effects of cardiopulmonary bypass on cell-mediated immune responses may lead to postoperative infectious complications. We previously reported that cimetidine reduced postbypass depression of the cytotoxic activity of natural killer cells. This study evaluated cimetidine as an agent to preserve cellular immunity after cardiac operations.
Methods: In a prospective randomized study, 20 patients were divided into two groups of equal size. Cimetidine-group patients received 400 mg of cimetidine intravenously before bypass and a 33 mg/hr intravenous infusion of cimetidine after the operation, continuing until the fifth postoperative day. Control-group patients received conventional perioperative therapy. Lymphocyte subsets, natural killer cell activity, percentage of CD56⁺CD16⁺ (percentage of natural killer cells), and percentage of CD11b⁺CD8⁺ (percentage of suppressor T lymphocytes) were measured perioperatively.
Results: Although temporary postoperative reductions in percentages of CD3⁺, CD4⁺, and CD56⁺CD16⁺ cells were observed in both groups, CD8⁺ percentages on postoperative day 1 and CD11b⁺CD8⁺ percentages on postoperative days 1 and 3 in the cimetidine group were significantly lower compared with those in the control group (p = 0.01, p = 0.004, and p = 0.02, respectively). Temporary postoperative reduction of natural killer cell activity was also observed in both groups, but the natural killer cell activity on postoperative day 1 in the cimetidine group (17.1%) was significantly higher (p = 0.02) than that in the control group (8.20%).
Conclusions: Cimetidine counteracts depressive effects of cardiopulmonary bypass on cell-mediated immunity and may possibly reduce postoperative susceptibility to infection.

This article has been cited by other articles:

				E. Tayama, N. Hayashida, S. Fukunaga, K. Tayama, T. Takaseya, R. Hiratsuka, and S. Aoyagi High-dose cimetidine reduces proinflammatory reaction after cardiac surgery with cardiopulmonary bypass Ann. Thorac. Surg., December 1, 2001; 72(6): 1945 - 1949. [Abstract] [Full Text] [PDF]